12 November 2026, Thursday
| Time | 12:30 – 13:15 (GMT+8) |
| Venue | Grand Hyatt Singapore, Residence 2, Level 3 |
| Synopsis | This presentation explores practical approaches to tissue handling and stapling in robotic-assisted thoracic surgery (RATS), with a focus on lobectomy and segmentectomy. The presentation will also highlight the role of the Signia™ Intelligent Stapling System and Tri-Staple™ technology in supporting controlled tissue compression, adaptive firing, and consistent stapling performance during thoracic procedures. |
| Objectives |
|
| Faculty |
Speaker: 
Padungkiat Tangpiroontham
Soon Sing Yang
|
Schedule
| Time | Agenda |
| 12:30 – 13:05 | Optimizing tissue management and stapling strategy during RATS lobectomy and segmentectomy. |
| 13:05 – 13:15 | Q&A |
13 November 2026, Friday
| Time | 11:45 – 12:30 (GMT+8) |
| Venue | Grand Hyatt Singapore, Grand Ballroom, Level 3 |
| Synopsis | This medical education event aims to strengthen clinician confidence in the practical peri-operative management of patients with stage II–IIIA resectable NSCLC, translating contemporary evidence into multidisciplinary, real-world decision-making. It will explore evolving strategies and practical considerations for selecting patients for peri-operative immunotherapy plus chemotherapy, while addressing key implementation challenges that can influence the pathway to surgery. Discussions will revolve around preserving surgical feasibility following neoadjuvant treatment through peri-operative MDT coordination, as well as identifying and managing treatment-related toxicities that may affect operability or outcomes. By sharing regional perspectives, practical experience and institutional best practices from across Asia-Pacific, the event seeks to support, coordinated clinical decision-making to improve patient outcomes. |
| Faculty | Chairperson:
Harish Mithiran
Raghavendra Mayya
|
Speakers:
Derek Huang
Rainbow Lau
|
Schedule
| Time | Agenda | Faculty |
| 11:45 – 11:48 | Welcome and faculty introduction |
Harish Mithiran
Raghavendra Mayya
|
| 11:48 – 12:08 | Surgical success in resectable NSCLC: Streamlining perioperative IO incorporation |
Rainbow Lau
|
| 12:08 – 12:28 | Maximising outcomes in resectable NSCLC: Real-world insights from KEYNOTE-671 |
Derek Huang
|
| 12:28 – 12:30 | Closing Remarks |
Harish Mithiran
Raghavendra Mayya
|
| Time | 11:45 -12:30 (GMT+8) |
| Venue | Grand Hyatt Singapore, Residence 5 & 6, Level 3 |
| Synopsis | Lung cancer remains the leading cause of cancer-related mortality worldwide, with most cases still diagnosed at an advanced stage. For thoracic surgeons, early detection is the cornerstone of curative resection. However, identifying ideal candidates for screening remains a significant clinical challenge. Notably, current guidelines do not recommend low-dose computed tomography (LDCT) screening for non-smokers, despite the rapidly rising incidence of adenocarcinomas among this Asian demographic.To bridge this critical diagnostic gap and expand screening accessibility, a 12-miRNA-CEA assay was developed specifically for the early detection of lung cancer. In the first part of the symposium, the clinical development and performance of the assay will be presented based on recently published data from a Japanese case-control validation cohort (Samejima et al., 2026). Enrolling 525 participants (cancer vs. matched controls), the study validated a proprietary 12-miRNA panel integrated with Carcinoembryonic Antigen (CEA). This model demonstrated exceptional diagnostic performance, achieving an Area Under the Curve (AUC) of 84.9% in the independent validation cohort and proving robust performance across diverse clinical scenarios.
Thoracic surgeons face several challenges in managing multi-focal lesions and distinguishing benign versus malignant lesions, especially when deciding which lesion to resect or when the decision differs from that of radiologists. Surgeons must weigh radiological and clinical risks, biopsy feasibility, and the consequences of a delayed diagnosis. The 12-miRNA-CEA assay serves as a powerful adjunctive tool to navigate this uncertainty. With up to 74% sensitivity and 97% specificity, the assay provides a molecular baseline to help risk-stratify both smokers and non-smokers, offering critical biological insights that complement imaging. The assay also provides a trackable risk score and risk category for longitudinal monitoring of risk progression over time to help guide surgical decision-making, thereby reducing unnecessary surgeries and ensuring timely curative resections. In the second part of the talk, we will discuss three real-world cases where the assay detected one case of Stage I lung adenocarcinoma and two cases of atypical adenomatous hyperplasia. This demonstrates the assay’s clinical utility in screening for early-stage cancers and precancerous lesions, particularly when suspicious LDCT nodules are reported as likely benign on Lung-RADS. |
| Objectives | Objective 1: Evaluate the clinical performance and screening value of the 12-miRNA-CEA assay. Objective 2: Assess the assay’s role in risk stratification and surgical decision-making. Objective 3: Analyze the real-world clinical utility of the assay alongside standard imaging. |
| Faculty |
Sai Sakktee Krisna
Aneez D.B. Ahmed
|
Schedule
| Time | Agenda | Faculty |
| 11:30 – 12:30 | Bridging the Screening Gap: Clinical Validation and Real-World Utility of a Novel 12-miRNA-CEA Assay in Early Lung Cancer | |
| 11:45 – 11:48 | Welcome and Faculty Introduction |
Sai Sakktee Krisna
|
| 11:48 – 12:08 | Pioneering Early Lung Cancer Screening Through microRNA Technology |
Sai Sakktee Krisna
|
| 12:08 – 12:23 | Early Detection in Practice: Real-World Utility of the 12-miRNA-CEA Assay |
Aneez D.B. Ahmed
|
| 12:23 – 12:30 | Closing remarks and Q&A |
Sai Sakktee Krisna
|
